| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
1,3Galactosyltransferase1
Departments of Microbiology and Immunology [D. C. L., S. Y. Z., U. G.] and Dermatology [J. T. A.], MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania 19129
A major prerequisite for the success of tumor vaccines is their effective uptake by antigen-presenting cells (APCs) and transport of these APCs to the draining lymph nodes, where the processed and presented tumor-associated antigens activate tumor-specific naive T cells. We previously suggested that the immunogenicity of autologous tumor vaccines in humans may be augmented by engineering vaccinating tumor cell membranes to express 
-galactosyl (-gal) epitopes (i.e., Gal1,3Galß1,4GlcNAc-R). Subsequent in situ binding of natural anti-Gal IgG molecules to these epitopes would result in the formation of immune complexes that target tumor vaccines for uptake by APCs, via the interaction of the Fc portion of anti-Gal with Fc
receptors on APCs. This hypothesis was tested in a unique experimental animal model of knockout mice for 1,3galactosyltransferase (1,3GT) and the mouse melanoma B16-BL6 (referred to here as BL6). Like humans, these mice lack -gal epitopes and produce anti-Gal. BL6 melanoma cells are highly tumorigenic, and like human tumor cells, they lack -gal epitopes. Expression of -gal epitopes on these melanoma cells was achieved by stable transfection with 1,3GT cDNA. The transfected melanoma cells (termed BL6GT) express 
2 x 106 -gal epitopes per cell and readily form immune complexes with anti-Gal.
Vaccination of the mice with 2 x 106 irradiated melanoma cells that express -gal epitopes, followed by challenge with 0.5 x 106 live parental melanoma cells, resulted in protection for at least 2 months (i.e., no tumor growth) in one-third of the mice, whereas all mice immunized with irradiated parental melanoma cells developed tumors 21–26 days post-challenge. The proportion of protected mice doubled when the mice were immunized twice with irradiated melanoma cells expressing -gal epitopes and challenged with 0.2 x 106 live BL6 cells. Histological studies on the developing tumors in challenged mice that were immunized with melanoma cells expressing -gal epitopes demonstrated extensive infiltration of T lymphocytes and macrophages, whereas no mononuclear cell infiltrates were observed in tumors of mice immunized with parental tumor cells.
Overall, these studies imply that immunization of 1,3GT knockout mice with BL6 melanoma cells that express -gal epitopes elicits, in a proportion of the population, protective immune response against the same tumor lacking such epitopes. These studies further suggest that similar immunization of cancer patients with autologous tumor vaccines that are engineered to express -gal epitopes may increase the immune response to autologous tumor-associated antigens and, thus, may elicit immune-mediated destruction of metastatic cells expressing these antigens.
This article has been cited by other articles:
|
|
 |
|
  U. M. Abdel-Motal, H. M. Guay, K. Wigglesworth, R. M. Welsh, and U. Galili Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting Cells J. Virol., September 1, 2007; 81(17): 9131 - 9141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-O. Sadoulet, C. Franceschi, M. Aubert, F. Silvy, J.-P. Bernard, D. Lombardo, and E. Mas Glycoengineering of {alpha}Gal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope Glycobiology, June 1, 2007; 17(6): 620 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Galili, K. Wigglesworth, and U. M. Abdel-Motal Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines J. Immunol., April 1, 2007; 178(7): 4676 - 4687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hewitt, H. Priddle, A. J. Thomson, D. Wojtacha, and J. McWhir Ablation of Undifferentiated Human Embryonic Stem Cells: Exploiting Innate Immunity Against the Gal {alpha}1-3Gal{beta}1-4GlcNAc-R ({alpha}-Gal) Epitope Stem Cells, January 1, 2007; 25(1): 10 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Abdel-Motal, S. Wang, S. Lu, K. Wigglesworth, and U. Galili Increased Immunogenicity of Human Immunodeficiency Virus gp120 Engineered To Express Gal{alpha}1-3Gal{beta}1-4GlcNAc-R Epitopes J. Virol., July 15, 2006; 80(14): 6943 - 6951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Rossi, M. R. Mautino, R. C. Unfer, T. M. Seregina, N. Vahanian, and C. J. Link Effective Treatment of Preexisting Melanoma with Whole Cell Vaccines Expressing {alpha}(1,3)-Galactosyl Epitopes Cancer Res., November 15, 2005; 65(22): 10555 - 10561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Suriano, S. K. Ghosh, B. T. Ashok, A. Mittelman, Y. Chen, A. Banerjee, and R. K. Tiwari Differences in Glycosylation Patterns of Heat Shock Protein, gp96: Implications for Prostate Cancer Prevention Cancer Res., July 15, 2005; 65(14): 6466 - 6475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Brady Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against Microbial Antigens Infect. Immun., February 1, 2005; 73(2): 671 - 678. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Unfer, D. Hellrung, and C. J. Link Jr. Immunity to the {alpha}(1,3)Galactosyl Epitope Provides Protection in Mice Challenged with Colon Cancer Cells Expressing {alpha}(1,3)Galactosyl-transferase: A Novel Suicide Gene for Cancer Gene Therapy Cancer Res., March 1, 2003; 63(5): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kalergis and J. V. Ravetch Inducing Tumor Immunity through the Selective Engagement of Activating Fc{gamma} Receptors on Dendritic Cells J. Exp. Med., June 17, 2002; 195(12): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Deriy, Z.-c. Chen, G.-P. Gao, and U. Galili Expression of {alpha}-gal epitopes on HeLa cells transduced with adenovirus containing {alpha}1,3galactosyltransferase cDNA Glycobiology, February 1, 2002; 12(2): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. C. Chen, M. Tanemura, and U. Galili Synthesis of {{alpha}}-gal epitopes (Gal{{alpha}}1-3Gal{beta}1-4GlcNAc-R) on human tumor cells by recombinant {{alpha}}1,3galactosyltransferase produced in Pichia pastoris Glycobiology, July 1, 2001; 11(7): 577 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Keusch, S. M. Manzella, K. A. Nyame, R. D. Cummings, and J. U. Baenziger Expression Cloning of a New Member of the ABO Blood Group Glycosyltransferases, iGb3 Synthase, That Directs the Synthesis of Isoglobo-glycosphingolipids J. Biol. Chem., August 11, 2000; 275(33): 25308 - 25314. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
